| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3274523 | Médecine des Maladies Métaboliques | 2014 | 8 Pages |
Abstract
Insulin degludec has a flat and stable profile at steady state, with less within-subject variability in glucose lowering activity from day to day. Long-acting insulin degludec has been studied in a large-scale clinical phase 3a trial program, examining its impact on glucose control, safety, hypoglycemia and the possibility to flexibly adjust insulin degludec dosing time to suit patient needs. More than 5,000 patients with type 1 or type 2 diabetes were enrolled.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
B. Cariou,